Atrial natriuretic factor: the heart as an endocrine organ

It has been known for some years that secretory granules exist within atrial myocytes, that the density of these granules is altered by changes in fluid balance, and that distention of the atria induces diuresis and natriuresis, and suppresses release of renin, aldosterone, and vasopressin. With the discovery that extracts of cardiac atria contain a potent natriuretic factor (ANF), that the granules are the storage site for ANF, and that atrial distention provokes ANF release, it became clear that the atria have both afferent and efferent functions in circulatory homoeostasis. However, ANF is not de Wardener’s ‘third factor’.

ANF is a 28 amino acid peptide which is released after cleavage of a 126 amino acid storage precursor and has a half life of 2–3 minutes. The only definite sources of circulating ANF are the cardiac atria but ANF also appears to be present in lung, brain, and fetal cardiac ventricles.

ANF release is stimulated by atrial distention, increase in intravascular volume, increased atrial pressure, and dietary sodium loading. ANF release is also provoked by infusion of α adrenergic agonists, angiotensin II, and antidiuretic hormone. ANF acts via a ‘second messenger’, cyclic guanosine monophosphate.

Actions of atrial natriuretic factor
Caution is needed here because of the unphysiological doses of ANF used in many studies. Studies in animals and adult man show that ANF has endocrine, renal, and vasomotor actions. Not only does ANF directly inhibit release of renin, aldosterone, and antidiuretic hormone, but ANF also antagonises the target organ effects of angiotensin II and antidiuretic hormone. As a result of these actions and of a paradoxical constrictive effect on the glomerular efferent arteriole, ANF causes an increase in glomerular filtration rate, and a diuresis and natriuresis. These actions suggest that antagonism of the renin-angiotensin-aldosterone system may represent a major function of ANF.

ANF administration is associated with a variable decrease in systemic blood pressure and a transient increase in regional blood flow to kidneys, lungs, and myocardium. ANF attenuates the pulmonary vasoconstriction induced by hypoxia and may act as a bronchodilator. ANF also induces a shift of fluid from the vascular to the extravascular space, possibly by increasing capillary leakiness. Finally, ANF may function as a neurotransmitter peptide and has direct effects on the central nervous system such as the inhibition of thirst.

Atrial natriuretic factor in the fetus
Fetal umbilical arterial ANF concentrations are not correlated with maternal concentrations and are the same or slightly higher. Umbilical artery ANF concentration is significantly greater than umbilical vein concentration, suggesting that the placenta consumes or takes up ANF. The human placenta has ANF binding sites and there is some evidence of a placental barrier to ANF transfer.

ANF concentrations increased appropriately in response to hypervolaemia and decreased with haemorrhage (R A Brace, C Y Cheung, personal communication) in the sheep fetus. In this model, fetal ANF also increased in response to hypoxia, which may be significant in view of the pulmonary vasodilator actions of ANF and fetal urine production increased in response to ANF. ANF concentrations were significantly raised in human fetuses undergoing cordocentesis for Rhesus isoimmunisation at 28 weeks’ gestation, and the ANF concentrations increase further after intrauterine transfusion. This suggests that in the human fetus, at least by the third trimester, ANF concentrations increase with pathological or iatrogenic volume expansion. Fetal ANF may also increase umbilical blood flow, and a decreased density of ANF receptors has been reported in placentas from pregnancies complicated by intrauterine growth retardation.

Atrial natriuretic factor in the newborn
The changes in right atrial pressure, glomerular filtration rate, and fluid balance that occur in the immediate postnatal period in normal term infants would suggest that ANF may have a physiological role. ANF may also have a role in respiratory illness as a diuresis occurs during the recovery phase of respiratory distress syndrome, and failure of such a diuresis may be predictive of the later development of bronchopulmonary dysplasia.

Normal values for ANF concentrations show no age variation beyond the neonatal period. ANF concentrations are only slightly raised in cord blood compared with later life, but they increase dramatically over the first few days in normal term infants and remain high throughout the first week of postnatal life. Although this increase in plasma ANF mirrors the course of postnatal negative salt and water balance, there was no correlation between ANF concentrations and urine sodium excretion. Dietary salt loading of premature infants increases plasma ANF, and this perhaps explains why previous attempts at manipulating intake to prevent early postnatal hyponatraemia have failed.

In premature infants with respiratory distress syndrome, we have also observed a significant increase in ANF concentrations over the first few days of life (T Stephenson, F Broughton Pipkin, D Hetmanski, unpublished observations), and they are higher the more severe the respiratory distress and highest during the diuretic phase. The ANF concentrations observed in these premature infants are much higher than in healthy term infants and yet, despite this, renin concentrations are also very high in the early postnatal period. Persistence of high ANF and antidiuretic hormone concentrations beyond early postnatal life may be associated with bronchopulmonary dysplasia.

Atrial natriuretic factor and cardiac disease in childhood
In the premature infant, plasma ANF concentrations were raised in the presence of a patent ductus arteriosus and fell with surgical ligation. In neonates with transposition of the great vessels, plasma ANF concentration correlated with left atrial pressure and ANF fell after septostomy. In older children with heart failure, the concentrations were above the normal range and fell after treatment. These authors suggested that ANF may be useful in the treatment of heart failure, as it may reduce both preload and afterload.
In children with septal defects, ANF concentrations were also increased and correlated with shunt size.23 Davis et al found that atrial pacing in children increased plasma ANF concentrations, although atrial pressure was unchanged, the increase in ANF being related to the increase in rate.24

This is consistent with the diuresis which follows episodes of supraventricular tachycardia.

Atrial natriuretic factor and renal disease in childhood
Normotensive children on maintenance haemodialysis have predialysis ANF concentrations which are significantly higher than ANF concentrations in normal children or children with advanced renal failure but no volume expansion.25 Plasma concentrations fell significantly during haemodialysis and the magnitude of this fall was directly related to the fall in body weight during dialysis.24 In animal models, prompt 'rescue' infusion of ANF after either noradrenaline or gentamicin induced renal failure significantly improved glomerular filtration rate, urine volume, and sodium excretion.2

Hypertension
In essential hypertension, ANF concentrations were normal in childhood but raised by adolescence.26 Whereas plasma ANF correlated with fractional and 24 hour urinary excretion of sodium in matched normotensive controls, no correlation was found in the smaller number of hypertensives. An impaired ANF response to high dietary salt intake has been reported in the offspring of hypertensive parents.27 These two studies suggest that in childhood essential hypertension, the contribution of ANF to sodium balance may be abnormal and this may help to clarify the complex pathogenesis and familial clustering of this condition.

Metabolic disorders
It has been suggested that Barter's syndrome may be a 'syndrome of inappropriate ANF secretion' (as these patients are volume contracted),28 but the raised ANF concentration may also be secondary. Gordon's syndrome may result from end organ insensitivity to ANF.29 ANF concentrations are increased in adults with endogenous or exogenous glucocorticoid excess30 and primary hyperaldosteronism28 and ANF falls to normal with treatment.

Summary
The growth in understanding about ANF over the last 10 years reflects the pace of modern biological research. Within three years of the initial report that atrial extract contained a natriuretic factor, human ANF was purified, sequenced, and cloned. Atrial dimension is the major determinant of ANF release, ANF has natriuretic and vasodilator effects, and ANF has a definite role in response to an acute increase in intravascular volume. It is not yet clear how important ANF is in the regulation of sodium and water balance and blood pressure under steady state, physiological conditions.

Most of our understanding is derived from experimental studies in animal models or from observational studies in adult man. The production of ANF by biotechnology allows interventional studies, however, and further advances may be made if specific antagonists of ANF can be developed. ANF may have therapeutic potential in the treatment of heart failure, respiratory distress syndrome, acute renal failure, oedema and ascites, systemic and pulmonary hypertension, and asthma. ANF antagonists might prevent hypernatraemia of prematurity and alleviate Barter's syndrome.

ANF is not nephrotoxic and is without many of the side effects of current diuretics and vasodilators but its use is currently limited by the very short half life and the need for intravenous administration.

T J STEPHENSON
Department of Child Health
F BROUGHTON PIPKIN
Department of Obstetrics
Queen's Medical Centre,
Nottingham NG7 2UH

28 Tuney TJ, Gordon RD. Plasma atrial natriuretic factor in primary aldosteronism (before and after treatment) and in Barter's and Gordon's syndromes. Lancet 1986;i:272-3.
Atrial natriuretic factor: the heart as an endocrine organ.

T J Stephenson and F Broughton Pipkin

Arch Dis Child 1990 65: 1293-1294
doi: 10.1136/adc.65.12.1293

Updated information and services can be found at:
http://adc.bmj.com/content/65/12/1293.citation

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/